More Stories

Informist, Tuesday, Nov. 11, 2025

 

Please click here to read all liners published on this story

--Biocon Jul-Sept consol EBITDA margin 21% vs 20% year ago 
--Biocon Jul-Sept consol EBITDA INR 9.28 bln vs INR 7.18 bln year ago 
--Biocon Q2 consol research svcs sales INR 9.11 bln vs INR 8.91 bln yr ago 
--Biocon Jul-Sept consol biosimilars revenue INR 27.21 bln vs INR 21.82 bln 
--Biocon Jul-Sept consol generics sales INR 7.74 bln vs INR 6.24 bln yr ago 
--Biocon Apr-Sept consol revenue INR 82.37 bln vs INR 70.23 bln year ago 
--Biocon Apr-Sept consol net profit INR 1.16 bln vs INR 6.44 bln yr ago 
--Biocon board OKs issuing commercial papers of up to INR 5.50 bln 
--Biocon Jul-Sept consol revenue INR 42.96 bln vs INR 35.90 bln year ago 
--Biocon Jul-Sept consol net profit INR 845 mln vs loss INR 160 mln yr ago 
--Analysts saw Biocon Jul-Sept consol revenue at INR 41.88 bln 
--Biocon Jul-Sept consol revenue INR 42.96 bln 
--Analysts saw Biocon Jul-Sept consol net profit at INR 850.20 mln 
--Biocon Jul-Sept consol net profit INR 845 mln

 

By Narayana Krishna

 

HYDERABAD - High double digit growth in both biologics and generics helped Biocon Ltd. to report a better-than-expected consolidated revenue for September quarter while its net profit was slightly below the estimates.

 

Bengaluru-based Biocon on Tuesday reported a consolidated net profit of INR 845 million for September quarter, against a net loss of INR 160 million a year ago. The company's revenue for the reporting quarter was up nearly 20% on year to INR 42.96 billion. Analysts' estimates for the company revenue was at INR 41.88 billion.

 

Biocon reported its biologics division revenue at INR 27.21 billion for the quarter, up nearly 25% on year. Biologics segment accounts for nearly 61% of the company's consolidated sales.

 

The company's September quarter generics business reported a 24% on-year rise to INR 7.74 billion. The contract development and manufacturing organization segment, which is under listed entity Syngene International Ltd., reported a 2.2% on-year growth in the September quarter revenue at INR 9.11 billion. 

 

From the trailing quarter, Biocon's net profit was seen up 169% due to low base and revenue 9%. Biocon said Jul-Sept business performance remained strong driven by robust growth in biosimilars, improved momentum in generics and steady contribution from contract research, development, and manufacturing organisation segment. The biologics segment growth was driven by autoimmune biosimilar drug Stelara sales in the US and diabetic drug Liraglutide in the UK and other European markets. The company has scheduled an investor call on Wednesday to detail its Jul-Sept performance.

 

Biocon said the board has approved a settlement of structured debt obligations, which will help the company strengthen its balance sheet, enhance financial flexibility, and improve margins.

 

For Jul-Sept, Biocon reported its earnings before interest, tax, depreciation, and amortisation margin at 21%, up 100 basis point on year. EIBTDA improved by 29% on year to INR 9.28 billion. The company's total expenses for the quarter rose 18.4% on year to INR 42.1 billion and other expenses rose 6.3% to INR 10.4 billion. The raw material costs for the quarter rose 35.5% on year to INR 13.7 billion. Biocon's research and development spending for the September quarter was up 25% on year at INR 2.51 billion.

 

Biocon board today approved issuing commercial papers of up to INR 5.5 billion in one or more tranches on a private-placement basis. The board also approved going for an early full redemption of non-convertible debentures aggregating to INR 5 billion.

 

For Apr-Sept, Biocon's consolidated net profit fell 82% on year to INR 1.16 billion but the revenue rose 17.3% on year to INR 82.37 billion. On Tuesday, Biocon shares ended at INR 385.10 on the National Stock Exchange, up nearly 0.8% from their previous close.  End

 

Edited by Akul Nishant Akhoury

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.